Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

I take a slightly different view.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
flipper44 Member Profile
Member Level 
Followed By 168
Posts 26,647
Boards Moderated 0
Alias Born 11/14/13
160x600 placeholder
SA Breaking News - PURA sees 2022 revenue upside potential to $10M InvestorsHub NewsWire - 12/15/2021 9:28:27 AM
Northwest Biotherapeutics secures $15M financing on stock purchase rights Seeking Alpha - 11/29/2021 11:11:27 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 4:41:30 PM
IQST Has Catalysts On Deck That Expose A Valuation Disconnect of Roughly 100% - Here's Why That Gap Should Close InvestorsHub NewsWire - 11/5/2021 10:20:59 AM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) InvestorsHub NewsWire - 10/29/2021 2:31:48 PM
Star Alliance Intl. Corp. (OTC Pink: STAL) Recent Gold Mine Acquisition NI43-101 InvestorsHub NewsWire - 10/29/2021 7:08:34 AM
IQST - EV & Hi-Tech Company Poised For Potential 4X ROI - Q3 Financials and Short Squeeze InvestorsHub NewsWire - 10/14/2021 11:34:44 AM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/11/2021 7:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth InvestorsHub NewsWire - 9/28/2021 7:24:31 AM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/27/2021 8:35:40 AM
CEO Presenting on the Emerging Growth Conference Tomorrow.  Register Now InvestorsHub NewsWire - 9/14/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 15.  Register Now InvestorsHub NewsWire - 9/13/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/31/2021 7:00:00 AM
CLS Holdings, (OTCQB: CLSH) July Sales $1.9 Million 104% increase over July 2019 InvestorsHub NewsWire - 8/17/2021 7:21:24 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2021 4:41:47 PM
CEO Presenting on the Emerging Growth Conference on August 4.  Register Now InvestorsHub NewsWire - 8/3/2021 7:00:00 AM
WSGF - World Series of Golf Inc VERY BULLISH Signal Continues InvestorsHub NewsWire - 8/2/2021 9:45:22 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on July 21 InvestorsHub NewsWire - 7/19/2021 7:00:00 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference Tomorrow.  Register Now InvestorsHub NewsWire - 7/6/2021 7:00:00 AM
Sino United (OTC Pink: SUIC) $200 Million Commitment, Signs with Suntech, the Largest Taiwan O2O Company. InvestorsHub NewsWire - 6/30/2021 7:30:00 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference Tomorrow!  Register Now InvestorsHub NewsWire - 6/22/2021 7:00:00 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 6/7/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/24/2021 4:35:22 PM
Northwest Bio gaining attention as investors await phase 3 GBM data Seeking Alpha - 5/24/2021 11:16:44 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/24/2021 7:03:10 AM
flipper44 Member Level  Wednesday, 07/07/21 06:35:33 AM
Re: sentiment_stocks post# 387846
Post # of 435914 
I take a slightly different view.

Without looking back up research done by AVII and others, I recall conditional survival phenomenon existed in long term survivors of GBM that received SOC in past years.

Bears like AVII and Ex have been saying “so what” if DCVax long term survivors have a better chance of surviving each consecutive year, that happens with SOC as well.

So, the solution is to see if the DCVax trial also beats external controls regarding this parameter. Hence the additional analysis.

My guess is that is perhaps one reason why, as I said a day or two ago, this trial ran on so long — because comparing conditional survival, by definition, requires a very mature set of data to reach statistical conclusions on longevity odds once impressive longevity already occurred in some patients.

This next point is also important. In the real world, those SOC long term survivors tend to be IDH mutant, which is a small subgroup WHO no longer considers a subset of GBM since 2021. However, our trial probably has/had very few patients with IDH mutant tumors, unlike prior GBM studies testing other treatments. Our trial, as Dr. Liau seems to infer from compassionate care and expanded use arms, probably is seeing long term conditional survival odds improve for IDH wild type, which is still considered GBM and is very rarely identified by long term survival when treated only by SOC.

Many people, hedge funds and others, in my opinion, don’t understand that it’s looking like NWBO is creating a true class of long term GBM survivors, whereas in the past, most long term survivors getting SOC therapy were, by today’s standards, not suffering from GBM.

Get vaccinated.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (5) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences